Thus, whilst PD-L1 expression on tumor cells has been considered as a critical mechanism of nivolumab’s anti-tumor activity, this factor was not proven as an essential determinant of clinical efficacy in NSCLC. This evidence concerns the gene CD274 and neoplasm.